New shot could tame high cholesterol without daily pills
NCT ID NCT07444086
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new injectable drug called QLC7401 in 510 adults with high cholesterol or mixed dyslipidemia who are not on other cholesterol treatments. Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see how much it lowers 'bad' LDL cholesterol over time. Researchers will also check safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QLC7401 injection
- What this could lead to
- If successful, this could provide a new injectable treatment option to help control high cholesterol and reduce heart disease risk.
- What could go wrong
- This is an early-stage Phase 3 trial, so results are not yet known. The drug may not lower cholesterol enough or could cause side effects. It is only tested in people not on other cholesterol meds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.